Allergy relief shake-up: Dr. Reddy’s launches generic Pataday 0.7% eye drops
Dr. Reddy’s launches first U.S. generic of Pataday 0.7% eye drops. Find out what this means for the OTC allergy market and Novartis’s branded edge.
Hyundai Bioscience begins U.S. Phase 2 trial of Xafty for COVID, flu, and RSV
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.
Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.
Intelligent Bio Solutions taps Syrma Johari to cut drug reader costs and prep for U.S. launch
INBS teams up with Syrma Johari to cut device costs, expand global output, and prep for a 2026 U.S. launch. Find out what this changes for fingerprint drug testing.